Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

LaNova Medicines and CTTQ Announces the IND Approval of Combination Therapies by NMPA

  • 2024-10-09

  • Share:

SHANGHAI, October 9th, 2024 – LaNova Medicines Ltd. announced that the investigational new drug (IND) for LM-108 in combination with CTTQ's benmelstobart injection/penpulimab, has been approved by China NMPA.

LM-108 is the targeted monoclonal antibody independently developed by LaNova Medicines; benmelstobart injection is an innovative humanized anti-PD-L1 monoclonal antibody; and penpulimab is a novel differentiated anti-PD-1 monoclonal antibody.